Atellica IM Hepatitis B core Antigen (aHBcM)
FDA premarket approval P030040/S012 · decided 2018-05-03
Approval details
- PMA number
- P030040
- Supplement
- S012
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Trade name
- Atellica IM Hepatitis B core Antigen (aHBcM)
- Generic name
- Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
- Applicant
- Siemens Healthcare Diagnostics
- Date received
- 2017-06-16
- Decision date
- 2018-05-03
- Days to decision
- 321 days
- Decision code
- APPR
- Product code
- LOM
- Advisory committee
- Microbiology
- Expedited review
- No
- Location
- East Walpole, MA
- Statement
- Approval for the migration of the ADVIA Centaur HBc IgM (aHBcM) assay to the Atellica IM Analyzer.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.